Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Anavex Life Sciences Corp./ 10-K

Annual Report · 10-K

Anavex Life Sciences Corp.

AVXLNASDAQEQUITYCurrent

Annual Report

Filed Dec 23, 2024Accepted Dec 23, 2024, 11:30 AM ESTCIK 1314052Accession 0001731122-24-002041
View company →Permanent SEC source ↗
Share

Company context

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical stage biopharmaceutical company engaged in the development of novel therapeutics for the treatment of central nervous system diseases with high unmet medical need. Further information is available at www.anavex.com.

Current securities

AVXLNASDAQ · EQUITY · Current

Recent company filings

  1. Other EventsOct 20, 2026
  2. Other EventsOct 15, 2026
  3. Changes in Control of Registrant · Submission of Matters to a Vote of Security HoldersSep 28, 2026
  4. DEFA14A filingSep 15, 2026
  5. DEFA14A filingSep 14, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.